Gastrointestinal Cancer

Deb Schrag, MD, MPH, will assume the role as ASCO president in 2027, and hopes to continue the work of transcending global, political, and geographic barriers in oncology.

In the phase 1/2 ReFocus trial, lirafugratinib demonstrated a median PFS of 11.3 months in the chemotherapy pretreated, FGR inhibitor-naïve CCA population.

People who consumed 14 or more drinks per week experienced a higher risk of colorectal cancer compared with those who consumed one or fewer drinks.

Data from the phase 3 PEAK trial demonstrate that bezuclastinib plus sunitinib may be favorable vs sunitinib alone in certain patients with GISTs.

Bezuclastinib plus sunitinib yielded favorable PFS and ORR data vs sunitinib alone in patients with previously treated gastrointestinal stromal tumors.

Data from 2 trials at the 2024 and 2025 ASCO Annual Meetings demonstrate the PD-L1/4-1BB bispecific antibody’s efficacy and safety in this population.

Toxicities with streptozotocin/5-fluorouracil and everolimus were comparable with other orally available chemotherapeutic schemes in this NET population.

Patients with pancreatic cancer who received up to 6 infusions of the multiantigen-targeted T cell product only experienced 1 treatment-related serious AE.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

Any-grade AEs were comparable between cadonilimab and a PD-1 monoclonal antibody regimen in this population, and no difference in grade 3/4 AEs emerged.

ACT5 of the PLAT study found radiotherapy dose escalation did not improve outcomes, safety, or QOL in patients with anal cancer.

In patients less likely to respond to neoadjuvant chemoradiation, postoperative adjuvant therapy may be a viable strategy in this ESCC group.

Data from a phase 1/2a trial show no dose-limiting toxicities associated with ELC-100 among patients with neuroendocrine tumors.

PFS and response rates were proved to be meaningful among patients receiving zolbetuximab plus mFOLFOX6 and nivolumab for metastatic gastric/GEJ cancer.

Any-grade AEs were observed in 91% of the pembrolizumab arm vs 82% of the placebo arm, with AEs leading to death in 1% of patients in both arms.

Data from the HERIZON-GEA-01 trial may support zanidatamab as a promising new standard in HER2-positive gastroesophageal adenocarcinoma.

Early data from the ABC-HCC trial showed an improvement in median time to failure of strategy with atezolizumab/bevacizumab vs TACE in this HCC population.

Consistent with FGFR2 inhibition, lirafugratinib was well-tolerated among patients with FGFR2-mutated cholangiocarcinoma in the ReFocus trial.

The primary end point of ORR was met in the CAR-like T-cell arm for patients with gastric/GEJ cancer.

The safety profile of chemoradiotherapy with or without tislelizumab was acceptable among patients with gastric cancer or gastroesophageal junction cancer.

Data from the CRITICS-II trial support total neoadjuvant chemotherapy plus chemoradiotherapy as a preferred candidate for future study in this population.

Results from arm A of a phase 1/2 trial showed improved efficacy with multi-antigen targeted T cells plus frontline chemotherapy.

Patients with gastric cancer who were treated with a 3-drug antiemetic regimen had lower discontinuation rates following the first zolbetuximab dose.

Overall survival and progression-free survival benefits with the combinations were consistent among prespecified subgroups based on PD-L1 status.

Larger-scale and longer-term studies could elucidate the mechanisms underlying quality of life benefits associated with resistance exercise in this group.